|
Friday, December 3, 2010 2:44 PM
|
Lindsay Harding
Acorda and the United States Food and Drug Administration recently reached an agreement on a pathway to getting Fampridine approved for this indication (improved walking). In addition to a Phase III trial currently underway, Acorda will work with the FDA''''s Special Protocol Assessment (SPA) to ensure their trial design proves that individuals treated with Fampridine-SR are significantly more likely to have consistent improvements in their walking than those treated with placebo...
|